Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

In a recent study posted to the bioRxiv* preprint server, researchers developed a novel bioinformatic algorithm to predict host cleavage targets of the SARS-CoV-2 3C-like protease (3CLPro).

23 Jan 2022

CENTOGENE teams up with Insilico Medicine to improve therapeutic targets for Niemann-Pick disease type C

A commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI) - driven drug discovery company, today announced a research and development collaboration to accelerate the discovery of novel therapeutic targets for Niemann-Pick disease type C

21 Jan 2022

New cryo-EM method may be able to shortcut a big step in modern vaccine development

Scientists at Scripps Research have devised a method that may be able to shortcut one of the big steps in modern vaccine development.

20 Jan 2022

Evaporators assist academic drug discovery

BioChromato Inc reports how the renowned Chemistry Research Laboratories (CRL) at Oxford University (UK) are using several Smart Evaporator C1 units to support their drug discovery activities in therapeutic areas including oncology and regenerative medicine.

From BioChromato Inc. 19 Jan 2022

Macrodomains represent a unique target for pathogens with pandemic potential

In a new study published in the journal Pathogens, researchers have summarized the role of the macrodomain in viral replication and virulence and further reviewed the development of macrodomain inhibitors as antiviral agents.

18 Jan 2022

MD Anderson and Eisbach Bio collaborate to develop precision oncology drugs

The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.

18 Jan 2022

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

PhoreMost Ltd today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park.

From PhoreMost 18 Jan 2022

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company.

From Malvern Panalytical 13 Jan 2022

TetraScience announces 300% ARR growth and 2021 achievements; prepares for next phase of growth

TetraScience, the R&D Data Cloud Company, is pleased to share highlights from a record-breaking 2021 fiscal year, including 300% annual recurring revenue growth, an $80M Series B funding round, and full operationalization of the Tetra Partner Network.

From TetraScience, Inc. 12 Jan 2022

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

The iMolecule group from Skoltech has developed an artificial intelligence-driven solution that uses data on the structure of RNA or DNA molecules to identify sites on them where interaction with potential drug candidates can occur.

11 Jan 2022

NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics

NeoCura and PhoreMost today announced an oncology drug discovery research collaboration.

From PhoreMost 11 Jan 2022

Providing recombinant antibody services and more within Europe

In this interview, News-Medical talks to Dr. Zhang Linlin, Technical Specialist at Sino Biological Europe, about their recombinant antibody services and more that they can provide within Europe. Image credit: Corona Borealis Studio/Shutterstock.com

From Sino Biological Inc. 11 Jan 2022

Therapeutic in vivo synthetic chemistry used to make anticancer drugs

An international research group at the RIKEN Cluster for Pioneering Research (CPR) has successfully treated cancer in mice using metal catalysts that assemble anticancer drugs together inside the body.

10 Jan 2022

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Model of neuromuscular junction could accelerate new treatments for neuromuscular diseases

The neuromuscular junction-;where nerves and muscle fibers meet-;is an essential synapse for muscle contraction and movement.

6 Jan 2022

Research may pave the way for designing new therapies to combat schistosomiasis

Neglected tropical diseases (NTDs) represent a group of about 20 conditions that affect more than a billion people worldwide.

6 Jan 2022

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

PhoreMost Limited and Polaris Quantum Biotech (POLARISqb) today announced a collaboration to study oncology targets currently considered undruggable.

From PhoreMost 6 Jan 2022

Horizontal gene transfer between viruses and hosts plays a major role in driving evolution

The first comprehensive analysis of viral horizontal gene transfer (HGT) illustrates the extent to which viruses pick up genes from their hosts to hone their infection process, while at the same time hosts also co-opt useful viral genes.

5 Jan 2022

Empire Discovery Institute collaborates with Novo Nordisk to launch new drug discovery initiative

Empire Discovery Institute entered into a five-year collaborative research partnership with global pharmaceutical company Novo Nordisk A/S to launch LeapRx, a new initiative where EDI and Novo Nordisk will co-invest, incubate and accelerate innovative drug discovery and development projects from its academic partners.

4 Jan 2022

Sino Biological Establishes New Location in Houston, Texas

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.

From Sino Biological Inc. 4 Jan 2022